Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 4/20 | 1.00 |
| ▸ | AOC3 | Q16853 | 12/20 | 0.67 |
| ▸ | AOC2 | O75106 | 2/20 | 0.60 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.54 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.54 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.54 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.54 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16048267 | 1.00 | KCNH2 (1.00) | KCNH2AOC3AOC2CYP19A1CYP2A6 | |
| SCHEMBL20924513 | 0.83 | AOC3 (0.74) | KCNH2AOC3AOC2 | |
| SCHEMBL30025875 | 0.81 | AOC3 (1.00) | KCNH2AOC3AOC2 | |
| SCHEMBL16048212 | 0.81 | AOC3 (1.00) | KCNH2AOC3AOC2 | |
| SCHEMBL30026678 | 0.79 | AOC3 (0.80) | KCNH2AOC3 | |
| SCHEMBL30026403 | 0.79 | AOC3 (0.79) | KCNH2AOC3 | |
| SCHEMBL16048226 | 0.79 | AOC3 (0.80) | KCNH2AOC3 | |
| SCHEMBL16048308 | 0.79 | AOC3 (0.79) | KCNH2AOC3 | |
| SCHEMBL16053490 | 0.76 | AOC3 (0.78) | KCNH2AOC3 | |
| SCHEMBL16048018 | 0.75 | AOC3 (1.00) | KCNH2AOC3AOC2CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230110165-A1 | Substituted Imidazo[4,5-c]pyridine Compounds and Compositions Thereof | PROXIMAGEN LLC (US) | 2023-04-13 | — | — | US | disclosed |
| US-11512082-B2 | Substituted imidazo[4,5-c]pyridine compounds and compositions thereof | PROXIMAGEN, LLC (US) | 2022-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11512082-B2 | Substituted imidazo[4,5-c]pyridine compounds and compositions thereof | PNPO, XDH, EPX | KCNH2 315/4885AOC3 12/4885AOC2 14/4885 |
| US-20230110165-A1 | Substituted Imidazo[4,5-c]pyridine Compounds and Compositions Thereof | PNPO, XDH, EPX | KCNH2 315/4885AOC3 12/4885AOC2 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.